PBLA OTC
Panbela Therapeutics, Inc.
1W: +0.0%
1M: +11000.0%
3M: +122.0%
YTD: -15.3%
1Y: -77.8%
3Y: -100.0%
5Y: -100.0%
$0.01
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$26M
+28.2% ▲
Operating Income
-$51M
-50.5% ▼
Net Income
-$25M
+27.7% ▲
EPS (Diluted)
$-232429.55
-470.4% ▼
EBITDA
-$51M
-47.6% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $4M | $6M | $10M | $36M | $26M |
| Gross Profit | -$4M | -$6M | -$10M | -$36M | -$26M |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $2M | $3M | $5M | $28M | $21M |
| SG&A Expenses | $2M | $3M | $5M | $6M | $5M |
| Operating Expenses | $4M | $6M | $10M | $34M | $26M |
| Operating Income | -$4M | -$6M | -$10M | -$34M | -$51M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $2M | $17K | $11K | $288K | -$317K |
| Income Before Tax | -$7M | -$5M | -$11M | -$35M | -$25M |
| Tax Expense | -$415K | -$295K | -$488K | -$116K | -$186K |
| Net Income | -$6M | -$5M | -$10M | -$35M | -$25M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-26103.83 | $-14798.10 | $-20773.70 | $-40748.57 | $-232429.55 |
| EBITDA | -$4M | -$5M | -$11M | -$35M | -$51M |
| Shares Outstanding | 238 | 322 | 488 | 857 | 109 |